Résultats de recherche

Retour
1 - 10 de 618 Résultats de recherche
 -  21 Septembre 2018

 -  21 Septembre 2018

Ipsen receives positive CHMP opinion for Cabometyx® (cabozantinib) for the second-line treatment of patients with hepatocellular carcinoma (HCC)

...

 -  29 Mai 2018

 -  29 Mai 2018

Ipsen and MD Anderson Announce Bench-to-Bedside Cancer Drug Development Partnership

...

 -  26 Juillet 2018

 -  26 Juillet 2018

Ipsen delivers strong results for the first half of 2018 with sales growth of 21.5% and upgrades its guidance for full year 2018

Attachment...

 -  29 Mai 2018

 -  29 Mai 2018

Ipsen announces clinical data to be presented at ASCO demonstrating its commitment to patients with cancer

...

 -  04 Juillet 2018

 -  04 Juillet 2018

Ipsen announces CELESTIAL phase 3 pivotal trial results in the New England Journal of Medicine

...

 -  19 Juillet 2018

 -  19 Juillet 2018

Ipsen and BioLabs to open new Innovation Center in Cambridge (U.S.) to foster development of new therapies for patients

Ipsen Innovation Center – BioLabs to be located in Ipsen’s new and third global hub in the heart of Cambridge, Massachusetts...

 -  17 Mai 2018

 -  17 Mai 2018

European Commission approves Ipsen’s Cabometyx® (cabozantinib) for the first-line treatment of adults with intermediate- or poor- risk advanced renal cell carcinoma 

...

 -  17 Mai 2018

 -  17 Mai 2018

La Commission européenne approuve Cabometyx® (cabozantinib) d’Ipsen en traitement de première ligne des adultes atteints d’un cancer du rein avancé à risque intermédiaire ou élevé 

...

 -  23 Mars 2018

 -  23 Mars 2018

Ipsen receives positive CHMP opinion for Cabometyx® (cabozantinib) for the first-line treatment of adults with intermediate- or poor- risk advanced renal cell carcinoma

...

 -  29 Janvier 2018

 -  29 Janvier 2018

Dr Sotirios G. Stergiopoulos appointed as Ipsen Chief Medical Officer

...

1 … 59 60 61 62